1. 1-24 of 90 1 2 3 4 »
    1. Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

      Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

      Conditions :   Childhood Solid Tumor;   Childhood Lymphoma Interventions :   Drug: Vinblastine;   Drug: Cyclophosphamide;   Drug: Capecitabine;   Drug: Nivolumab Sponsors :   Centre Oscar Lambret;   Anticancer Fund, Belgium;   Bristol-Myers Squibb Not yet recruiting

      Read Full Article
    2. Investigating the Microbiome and Volatilome of Children With Neuroblastoma

      Investigating the Microbiome and Volatilome of Children With Neuroblastoma

      Conditions :   Microbial Colonization;   Neuroblastoma;   Children, Only Interventions :   Diagnostic Test: Initial fecal microbiome;   Diagnostic Test: Initial fecal volatile organic compounds;   Diagnostic Test: Initial breath volatile organic compounds;   Diagnostic Test: Microbiome under chemotherapy;   Diagnostic Test: Fecal volatile organic compounds under chemotherapy;   Diagnostic Test: Breath volatile organic compounds under chemotherapy;   Diagnostic Test: Final microbiome;   Diagnostic Test: Final fecal volatile organic compounds;   Diagnostic Test: Final breath volatile organic compounds Sponsor :   Medical University of Graz Recruiting

      Read Full Article
      Mentions: Chemotherapy
    3. Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

      Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

      Conditions :   Childhood Solid Tumor;   Childhood Lymphoma;   Relapsed Cancer;   Refractory Cancer;   Adult Solid Tumor;   Adult Lymphoma Interventions :   Drug: Pembrolizumab;   Drug: Decitabine;   Radiation: Hypofractionated Index Site Radiation Sponsor :   Children's Hospital Medical Center, Cincinnati Recruiting

      Read Full Article
    4. PRecISion Medicine for Children With Cancer

      PRecISion Medicine for Children With Cancer

      Conditions :   Childhood Cancer;   Childhood Solid Tumor;   Childhood Brain Tumor;   Childhood Leukemia;   Refractory Cancer;   Relapsed Cancer Intervention :   Diagnostic Test: Molecular profiling and drug testing Sponsors :   Sydney Children's Hospitals Network;   Children's Cancer Institute Australia;   Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG);   Garvan Institute of Medical Research;   German Cancer Research Center (DKFZ) Recruiting

      Read Full Article
    5. GD2 Specific CAR and Interleukin-15 Expressing Autologous NK T-cells to Treat Children With Neuroblastoma

      GD2 Specific CAR and Interleukin-15 Expressing Autologous NK T-cells to Treat Children With Neuroblastoma

      Condition :   Neuroblastoma Interventions :   Genetic: GINAKIT Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine Sponsors :   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital Not yet recruiting

      Read Full Article
      Mentions: T-Cells
    6. A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

      Conditions :   Relapsed or Refractory Malignancies;   Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL);   Relapsed or Refractory Acute Myeloid Leukemia (AML);   Relapsed or Refractory Non-Hodgkin Lymphoma (NHL);   Relapsed or Refractory Neuroblastoma;   Relapsed or Refractory Tumors That Expresses B Cell Lymphoma 2 (BCL-2) Interventions :   Drug: venetoclax;   Drug: chemotherapy Sponsors :   AbbVie;   Genentech/Roche Not yet recruiting - verified July 2017

      Read Full Article
      Mentions: Refractory
    7. Pediatric MATCH: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations

      Conditions :   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   ALK Gene Translocation;   Histiocytosis;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation;   ROS1 Gene Translocation;   Stage III Childhood Non-Hodgkin Lymphoma;   Stage IV Childhood Non-Hodgkin Lymphoma Interventions :   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study Sponsor :   National Cancer Institute (NCI) Not yet recruiting - verified July 2017

      Read Full Article
      Mentions: Refractory ALK
    8. Pediatric MATCH: Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations

      Conditions :   Advanced Malignant Solid Neoplasm;   BRAF Gene Mutation;   GNA11 Gene Mutation;   GNAQ Gene Mutation;   Histiocytosis;   HRAS Gene Mutation;   KRAS Gene Mutation;   NF1 Gene Mutation;   NRAS Gene Mutation;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Stage III Childhood Non-Hodgkin Lymphoma;   Stage IV Childhood Non-Hodgkin Lymphoma Interventions :   Other: Laboratory Biomarker Analysis;   Drug: Selumetinib Sponsor :   National Cancer Institute (NCI) Not yet recruiting - verified July 2017

      Read Full Article
      Mentions: Refractory
    9. Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR 1/2/3/4 Mutations

      Conditions :   Advanced Malignant Solid Neoplasm;   FGFR1 Gene Mutation;   FGFR2 Gene Mutation;   FGFR3 Gene Mutation;   FGFR4 Gene Mutation;   Histiocytosis;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Stage III Childhood Non-Hodgkin Lymphoma;   Stage IV Childhood Non-Hodgkin Lymphoma Interventions :   Other: Laboratory Biomarker Analysis;   Drug: pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493;   Other: Pharmacological Study Sponsor :   National Cancer Institute (NCI) Not yet recruiting - verified June 2017

      Read Full Article
      Mentions: Refractory
    10. An International Multicenter Phase II Randomised Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy

      Condition :   Very High Risk Neuroblastoma Interventions :   Radiation: 131I- mIBG;   Drug: Topotecan;   Drug: Thiotepa;   Procedure: Autologous stem cell transplant Sponsors :   Gustave Roussy, Cancer Campus, Grand Paris;   SIOPEN;   French National Cancer Institute Not yet recruiting - verified May 2017

      Read Full Article
    11. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

      Conditions :   Childhood Ganglioneuroblastoma;   Childhood Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma Interventions :   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate Sponsors :   Children's Oncology Group;   National Cancer Institute (NCI) Not yet recruiting - verified April 2017

      Read Full Article
    12. Response-based Treatment of High-risk Neuroblastoma

      Condition :   Newly Diagnosed High Risk Neuroblastoma Interventions :   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Carboplatin;   Procedure: Tandem HDCT/auto-SCT;   Radiation: Radiotherapy;   Drug: Interleukin-2;   Drug: Isotretinoin;   Radiation: MIBG Sponsor :   Samsung Medical Center Recruiting - verified May 2016

      Read Full Article
    1-24 of 90 1 2 3 4 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video